NCT03380390View on ClinicalTrials.gov

Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 4, 2017

Primary Completion Date

June 15, 2018

Study Completion Date

June 15, 2018

Conditions
Rosacea
Interventions
DRUG

Oxymetazoline HCL 1.0% Cream

Oxymetazoline HCl cream 1.0% once daily application

DEVICE

Energy-Based Therapy

Energy-based therapies (Potassium Titanyl Phosphate \[KTP\], Pulsed Dye Laser \[PDL\], or Intense Pulsed Light \[IPL\])

Trial Locations (4)

10016

Laser & Skin Surgery Center of New York Professional Corporation, New York

95819

Center for Dermatology and Laser Surgery, Sacramento

02467

SkinCare Physicians, Chestnut Hill

07601

Skin Laser and Surgery Specialists of NY/NJ, Hackensack

Sponsors
All Listed Sponsors
lead

Aclaris Therapeutics, Inc.

INDUSTRY